Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
247
datasets available to search
ShareScore release 0.9.0
Dataset results
247 results for “secondary prevention”
Dataset related to article "ANTIHYPERTENSIVE DRUGS FOR SECONDARY PREVENTION AFTER ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK"
<p>we performed a systematic review and meta-analysis in order to summarize the current evidence on blood pressure (BP)-lowering drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack. We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials up to January 31, 2020. We included randomized controlled trials comparing any specific BP-lowering drug, as monotherapy or combination, with either a control or another BP-lowering drug. Eight studies that enrolled 33 774 patients with ischemic stroke or transient ischemic attack were included in the meta-analysis. Primary outcomes were all-cause mortality and the proportion of patients who developed a stroke following BP-lowering drug use, irrespective of its nature (ischemic or hemorrhagic) and severity. Secondary outcomes included the proportion of patients who developed an ischemic stroke; an ischemic stroke or TIA irrespective of severity; a hemorrhagic stroke, defined as an acute extravasation of blood into and around the brain parenchyma (subdural hematoma and epidural hematoma were excluded); a cardiovascular event defined as any sudden death, fatal or nonfatal acute coronary syndrome, stroke, intracranial hemorrhage, or pulmonary embolism; a fatal cardiovascular event defined as any death due to any vascular cause, including unexplained sudden death; and serious adverse events of hypotension, syncope, injurious falls, electrolyte abnormalities, bradycardia, or acute renal failure. We recorded the outcomes at the longest available follow-up for all analyses. We considered the following potential sources of heterogeneity (effect modifiers): inclusion limited to hypertensive patients (normotensive and hypertensive patients versus hypertensive patients only) or noncardioembolic ischemic strokes (all ischemic strokes versus noncardioembolic ischemic strokes only), time from the index ischemic event to randomization (acute patients treated within the first week versus stabilized patients treated after the first week), and trial risk of bias.</p>
Assessing the Nature and Quality of Emergency Obstetric Care for Preventing Maternal and Perinatal Mortality in 8 Secondary and Tertiary Hospitals in Nigeria: Results of a Formative Research Study
<p>Nigeria suffers some of the highest rates of maternal and perinatal mortality in the world. Poor quality of obstetric care is a key factor, and although not quantified at a national level, local studies suggest that high rates of maternal and perinatal deaths are due to clinical management errors in hospitals. This project therefore explored the nature of existing practices and quality of clinical management of three leading causes of maternal and perinatal deaths (primary postpartum haemorrhage, eclampsia, and obstructed labour); implement an intervention package aimed at improving the quality of clinical management of these causes of deaths; and test the effectiveness of this package on quality of care indicators and maternal and perinatal outcomes. </p> <p>The study follows a quasi-experimental research design, using interrupted time series analysis for assessment over a three year period. Six public secondary care hospitals and two public tertiary care hospitals in both north and south of Nigeria were selected randomly. Formative research was conducted in all eight hospitals, and thereafter the intervention will be carried out in four hospitals, with the remaining four hospitals functioning as control sites. </p> <p>Clinical outcomes will be compared between intervention and control sites in a total of 2334 cases of PPH, preeclampsia/eclampsia and obstructed labour (based on an anticipated 50% reduction in case fatality rates, significance level of 0.05 and 80% power). This will consist of 1167 cases in the intervention sites and 1167 in the control sites. Maternal and perinatal mortality rates will serve as primary outcome measures. Secondary outcomes involve quality of care drawn from United Nations process indicators, skilled attendance index and data derived from this formative audit phase of the project.</p> <p>The results will enable the identification of a system-wide quality of care framework for improving the delivery of emergency obstetric care for the prevention of maternal and perinatal morbidity and mortality in Nigeria.</p>
Assessing the Nature and Quality of Emergency Obstetric Care for Preventing Maternal and Perinatal Mortality in 8 Secondary and Tertiary Hospitals in Nigeria: Results of a Formative Research Study
<p>Nigeria suffers some of the highest rates of maternal and perinatal mortality in the world. Poor quality of obstetric care is a key factor, and although not quantified at a national level, local studies suggest that high rates of maternal and perinatal deaths are due to clinical management errors in hospitals. This project therefore explored the nature of existing practices and quality of clinical management of three leading causes of maternal and perinatal deaths (primary postpartum haemorrhage, eclampsia, and obstructed labour); implement an intervention package aimed at improving the quality of clinical management of these causes of deaths; and test the effectiveness of this package on quality of care indicators and maternal and perinatal outcomes. </p> <p>The study follows a quasi-experimental research design, using interrupted time series analysis for assessment over a three year period. Six public secondary care hospitals and two public tertiary care hospitals in both north and south of Nigeria were selected randomly. Formative research was conducted in all eight hospitals, and thereafter the intervention will be carried out in four hospitals, with the remaining four hospitals functioning as control sites.</p> <p>Clinical outcomes will be compared between intervention and control sites in a total of 2334 cases of PPH, preeclampsia/eclampsia and obstructed labour (based on an anticipated 50% reduction in case fatality rates, significance level of 0.05 and 80% power). This will consist of 1167 cases in the intervention sites and 1167 in the control sites. Maternal and perinatal mortality rates will serve as primary outcome measures. Secondary outcomes involve quality of care drawn from United Nations process indicators, skilled attendance index and data derived from this formative audit phase of the project.</p> <p>The results will enable the identification of a system-wide quality of care framework for improving the delivery of emergency obstetric care for the prevention of maternal and perinatal morbidity and mortality in Nigeria</p>
The effects of primary or secondary prevention with vitamin A supplementation on clinically important outcomes. A systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis
<p>Meta data for the review entitled "The effects of primary or secondary prevention with vitamin A supplementation on clinically important outcomes. A systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis<strong>"</strong></p>
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
ClinicalTrials.gov study NCT02694185. IPD Sharing: NO. Countries: 2. Publications: 7.
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
ClinicalTrials.gov study NCT02596230. IPD Sharing: UNDECIDED. Countries: 37. Publications: 3.
Secondary Prevention of Osteoporosis
ClinicalTrials.gov study NCT00421343. IPD Sharing: Not stated. Countries: 1. Publications: 5.
A Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease
ClinicalTrials.gov study NCT01688141. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
ClinicalTrials.gov study NCT06312683. IPD Sharing: YES. Countries: 1. Publications: 96.
Secondary HIV Prevention and Adherence Among HIV-infected Drug Users
ClinicalTrials.gov study NCT01741311. IPD Sharing: Not stated. Countries: 1. Publications: 2.
The SUCCEED Trial of Secondary Stroke Prevention
ClinicalTrials.gov study NCT01763203. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
ClinicalTrials.gov study NCT02313909. IPD Sharing: Not stated. Countries: 31. Publications: 15.
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
ClinicalTrials.gov study NCT03190967. IPD Sharing: YES. Countries: 1. Publications: 5.
School Nurse-directed Secondary Obesity Prevention for Elementary School Children
ClinicalTrials.gov study NCT02029976. IPD Sharing: NO. Countries: 1. Publications: 9.
Secondary Prevention of Venous Thrombo Embolism (VTE).
ClinicalTrials.gov study NCT00329238. IPD Sharing: Not stated. Countries: 33. Publications: 3.
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
ClinicalTrials.gov study NCT03080883. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
ClinicalTrials.gov study NCT02239120. IPD Sharing: Not stated. Countries: 42. Publications: 7.
Secondary Prevention of Cardiovascular Disease in the Elderly Trial
ClinicalTrials.gov study NCT02596126. IPD Sharing: Not stated. Countries: 7. Publications: 2.
An Assessment of an HIV Prevention Intervention (Project AIM) Among Junior Secondary School Students in Eastern Botswana
ClinicalTrials.gov study NCT02455583. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer
ClinicalTrials.gov study NCT07233863. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.